RetinAI acquired by EssilorLuxottica to advance AI-powered eye care
15.10.2025
EssilorLuxottica has acquired RetinAI, a medtech company that uses AI to analyze retinal images and data. The acquisition puts RetinAI’s technology at the heart of the Group’s strategy, helping doctors detect eye diseases faster and make more informed decisions for patient care.
 |
 |
RetinAI develops innovative software that collects, processes, and analyzes large-scale retinal images and biomarker datasets. Its flagship platform, RetinAI Discovery, FDA-cleared and CE-marked, uses AI models to support the diagnosis and monitoring of eye conditions such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy. By providing actionable insights, RetinAI helps healthcare professionals make more informed and timely decisions in patient management.
From the very beginning, the Medtech company's goal has been to harness the power of data and AI to transform patient care. This next chapter with EssilorLuxottica allows it to take that mission further—scaling its impact globally and strengthening its contribution to the future of patient care.
Beyond clinical applications, RetinAI collaborates with pharmaceutical companies and research organizations to accelerate drug development and clinical studies. Its AI-driven platform leverages real-world evidence to streamline workflows across clinical, research, and pharmaceutical domains.
Being acquired by EssilorLuxottica enables RetinAI to scale its technology globally, integrating its AI-powered solutions into a leading eyecare ecosystem. The move highlights RetinAI’s role in redefining eye health through advanced data, machine learning, and retinal imaging.
RetinAI has been ranked among the Top100 Swiss Startups, won Venture Kick, and participated in Venture Leaders Life Sciences and Venture Leaders China.
RetinAI team
From the very beginning, the Medtech company's goal has been to harness the power of data and AI to transform patient care. This next chapter with EssilorLuxottica allows it to take that mission further—scaling its impact globally and strengthening its contribution to the future of patient care.
Beyond clinical applications, RetinAI collaborates with pharmaceutical companies and research organizations to accelerate drug development and clinical studies. Its AI-driven platform leverages real-world evidence to streamline workflows across clinical, research, and pharmaceutical domains.
Being acquired by EssilorLuxottica enables RetinAI to scale its technology globally, integrating its AI-powered solutions into a leading eyecare ecosystem. The move highlights RetinAI’s role in redefining eye health through advanced data, machine learning, and retinal imaging.
RetinAI has been ranked among the Top100 Swiss Startups, won Venture Kick, and participated in Venture Leaders Life Sciences and Venture Leaders China.
RetinAI team